Phagenesis completes $42M Series D financing for swallowing disorder treatment expansion.
Phagenesis, a UK-based medical company, successfully completes $42M Series D financing. The company focuses on treating swallowing disorders with their Phagenyx® neurostimulation system, targeting neurological components disrupted due to brain injury. Funds will be used for expansion, development, US commercialization, European penetration, clinical trials, regulatory activities, and pipeline product research.
March 04, 2024
3 Articles